Details of the Drug Combination

General Information of Drug Combination (ID: DC3SWDM)

Drug Combination Name
Dapagliflozin Exenatide
Indication
Disease Entry Status REF
Evaluate Ketogenic Stress Phase 1 [1]
Component Drugs Dapagliflozin   DM28UJG Exenatide   DMYHBKN
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Dapagliflozin
Disease Entry ICD 11 Status REF
Non-insulin dependent diabetes 5A11 Approved [2]
Type-2 diabetes 5A11 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Dapagliflozin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Sodium/glucose cotransporter 2 (SGLT2) TTLWPVF SC5A2_HUMAN Modulator [8]
------------------------------------------------------------------------------------
Dapagliflozin Interacts with 7 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [9]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [9]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [9]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Metabolism [9]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)
Dapagliflozin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Sodium/glucose cotransporter 2 (SLC5A2) OT93UUDI SC5A2_HUMAN Decreases Activity [10]
------------------------------------------------------------------------------------
Indication(s) of Exenatide
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Approved [5]
Non-insulin dependent diabetes 5A11 Approved [5]
Type-1/2 diabetes 5A10-5A11 Approved [5]
Type-2 diabetes 5A11 Approved [6]
Cardiovascular disease BA00-BE2Z Phase 3 [7]
Exenatide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Binder [11]
------------------------------------------------------------------------------------
Exenatide Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Dipeptidyl peptidase IV (DPP4) DEKZQY6 DPP4_HUMAN Metabolism [12]
------------------------------------------------------------------------------------
Exenatide Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [13]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Obesity DCEBEX7 N. A. Phase 2 [14]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02962492) An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
2 Dapagliflozin FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4594).
4 Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19)
5 Exenatide FDA Label
6 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
9 Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
10 Discovery of novel N--D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. J Med Chem. 2011 Jan 13;54(1):166-78. doi: 10.1021/jm101072y. Epub 2010 Dec 3.
11 Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
12 In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. PLoS One. 2015 Feb 27;10(2):e0116805.
13 Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release. 2010 Mar 3;142(2):206-13. doi: 10.1016/j.jconrel.2009.10.025. Epub 2009 Nov 10.
14 ClinicalTrials.gov (NCT02313220) Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight